共 50 条
- [41] Targeting SAMHD1 Promotes Anti-Tumor Immunity in Acute Myeloid LeukemiaBLOOD, 2022, 140Zhang, LeiDong, HaojieHe, XinLin, YichunHu, WeidongSalhotra, AmandeepArmenian, Saro H.Marcucci, GuidoLuo, YunLi, Ling
- [42] Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibodyEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 267Zeng, ShenxinWu, MingfeiJin, YuyuanYe, YingqiaoXia, HeyeChen, XinyiChe, JinxinWang, ZunyuanWu, YingDong, XiaowuChen, YinqiaoHuang, Wenhai
- [43] Discovery of CC-91516, a potent and selective ERK/NLK inhibitor, with anti-tumor activity in preclinical cancer models harboring BRAF or CTNNB1 mutationCANCER RESEARCH, 2022, 82 (12)Xu, ShuichanTran, TamZhu, DanShi, TaoMikolon, DavidLeisten, JimChamberlain, PhilipLeBrun, LaurieBahmanyar, SogoleJiang, NingZhao, JingjingMalek, MehnazFilvaroff, EllenRaymon, HeatherHubbard, RobertBoylan, John
- [44] Discovery and Development of SPR519 as a Potent, Selective, and Orally Bioavailable Inhibitor of PI3Kα and mTOR Kinases for the Treatment of Solid TumorsJOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11121 - 11130Mahajan, DineshSen, SomduttaKuila, BilashSharma, AmitArora, ReenaSagar, MilindMahapatra, Amal RayGawade, Lalita BabasahebDugar, Sundeep
- [45] Discovery of potent and selective bivalent CDK2 degraders that demonstrate activity in CCNE1amp driven tumorsCANCER RESEARCH, 2024, 84 (06)Gerson-Gurwitz, AdinaYang, PengyuFish, SarahBlanco, GabrielleGao, HongfengHayashi, KyoheiHocker, MikeJamborcic, AleksRichters, AndreSpalding, Mary E.Toth, JuliaDuc TranYang, LinetteYou, ShuBurritt, AndrewCampos, AlexParker, GregoryFreeman-Cook, KevinThompson, Peggy A.Bailey, Simon
- [46] Discovery of SC110237, a highly potent, selective and orally active FLT3 inhibitor for the treatment of acute myeloid leukemiaCANCER RESEARCH, 2015, 75Kong, NormanGao, DaxinYang, HepingYu, Yajun
- [47] Discovery and characterization of a p300-selective degrader with potent anti-tumor activity in CBP mutant cancersCANCER RESEARCH, 2024, 84 (06)Russell, Mike R.Lowenstein, Cassandra L.Zhang, XuqingRoach, JeremySong, JianingNagilla, RakeshKendsersky, NathanJoshi, ShreyasOrth, PeterTudor, MattDeng, QiaolinAguilar-Bonavides, ClementeBehshad, ElhamBanjade, SudeepSui, ZhihuaStrickland, CoreyJolivette, LarryMohammad, Helai P.
- [48] RGT-264 a highly potent, selective and orally bioavailable HPK1 (MAP4K1) inhibitor augments immune activation and anti-tumor immunityEUROPEAN JOURNAL OF CANCER, 2024, 211 : S172 - S173Xiao, F.Liu, H.Wu, L.Feng, S.Liu, Y.Xiao, H.Li, H.Huang, W.Ren, X.Ren, B.Yao, L.Lin, J.Zhong, W.Xie, Z.
- [49] Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft ModelsBLOOD, 2020, 136Hiemstra, Ida H.Janmaat, Maarten L.Boross, PeterVan den Brakel, Jeroenten Hagen, Wesselvan Dooremalen, SanneBosgra, SietoDe Goeij, Bart E. C. G.Andringa, GrietjeKil, LaurensSasser, A. KateAhmadi, TahamtanSatijn, DavidBreij, Esther C. W.
- [50] The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER plus breast cancerMOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)Palanisamy, Gopinath S.Venkateshappa, ChandregowdaGoyal, MeghaBarrett, Susanna A.Heam, Brian R.Daginakatte, GirishAravind, A. B.Samiulla, D. S.Bera, KalisankarSangeetha, S.Khare, LeenaParisian, Alison D.Heerding, Dirk A.Ng, Raymond A.Harmon, Cyrus L.Samajdar, SusantaRamachandra, MuraliMyles, David C.